소아에서 시행한 초급속 면역 치료의 안전성
Safety of ultrarush allergen subcutaneous immunotherapy in children with allergic disease
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Ultrarush immunotherapy (ultra-RIT) is more convenient and higher compliant than conventional immunotherapy, but it has rarely used in clinical practice due to severe systemic reactions. This study aimed to determine the safety of ultra-RIT in children and adolescents. Methods: We investigated 19 patients who received ultra-RIT with the same schedule between January 2011 and May 2016. They were sensitized to house dust mites (HDMs) and/or pollen and had their symptoms associated with positive allergens. Over a 1-day hospitalization period, all patients received ultra-RIT subcutaneously 3 times, increasing at hourly intervals. Systemic reactions were classified according to the World Allergy Organization grade system. Results: Systemic reactions occurred in 14 patients (73.7%). The mean time to adverse reactions after the last injection was 36 minutes, and the majority of systemic reactions were pruritus and urticaria. In addition, the injection of HDM alone or HDM plus pollen caused more than grade 2 systemic reactions in about 50% each of the patients. Conclusion: Since ultra-RIT caused a higher incidence of systemic reactions in children and adolescents, it should be carried out cautiously in the hospitalization rather than the office.
Abstract
Purpose: Ultrarush immunotherapy (ultra-RIT) is more convenient and higher compliant than conventional immunotherapy, but it has rarely used in clinical practice due to severe systemic reactions. This study aimed to determine the safety of ultra-RIT in children and adolescents. Methods: We investigated 19 patients who received ultra-RIT with the same schedule between January 2011 and May 2016. They were sensitized to house dust mites (HDMs) and/or pollen and had their symptoms associated with positive allergens. Over a 1-day hospitalization period, all patients received ultra-RIT subcutaneously 3 times, increasing at hourly intervals. Systemic reactions were classified according to the World Allergy Organization grade system. Results: Systemic reactions occurred in 14 patients (73.7%). The mean time to adverse reactions after the last injection was 36 minutes, and the majority of systemic reactions were pruritus and urticaria. In addition, the injection of HDM alone or HDM plus pollen caused more than grade 2 systemic reactions in about 50% each of the patients. Conclusion: Since ultra-RIT caused a higher incidence of systemic reactions in children and adolescents, it should be carried out cautiously in the hospitalization rather than the office.
참고문헌 (36)
- Jutel M, "International consensus on allergy immunotherapy", J Allergy Clin Immunol, 136, pp.556~568 (2015)
- Roche AM, "Subcutaneous immunotherapy", Int Forum Allergy Rhinol, 4(Suppl 2), pp.S51~S54 (2014)
- Cox L, "Accelerated immunotherapy schedules: review of efficacy and safety", Ann Allergy Asthma Immunol, 97, pp.126~137 (2006)
- Des Roches A, "Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children", J Allergy Clin Immunol, 99, pp.450~453 (1997)
- Purello-D'Ambrosio F, "Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study", Clin Exp Allergy, 31, pp.1295~1302 (2001)
- Rhodes BJ, "Patient dropouts before completion of optimal dose, multiple allergen immunotherapy", Ann Allergy Asthma Immunol, 82, pp.281~286 (1999)
- 현세은, "집먼지 진드기 항원을 이용한 초급속면역치료의 안전성과 효과", Korean Journal of Pediatrics, 51(8), pp.868~873 (2008), 대한소아과학회
- 김명은, "Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis", Journal of Korean Medical Science, 26(9), pp.1159~1164 (2011), 대한의학회
- Castro-Rodríguez JA, "A clinical index to define risk of asthma in young children with recurrent wheezing", Am J Respir Crit Care Med, 162(4 Pt 1), pp.1403~1406 (2000)
- Crapo RO, "Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999", Am J Respir Crit Care Med, 161, pp.309~329 (2000)
- "Korean Guideline for Asthma" (2015)[URL]
- Brozek JL, "Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision", J Allergy Clin Immunol, 126, pp.466~476 (2010)
- Esch RE, "Allergen immunotherapy: what can and cannot be mixed?", J Allergy Clin Immunol, 122, pp.659~660 (2008)
- Calderón MA, "Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence", J Allergy Clin Immunol, 129, pp.929~934 (2012)
- Lee KU, "A study on the method of exclusion on unnecessary allergens from the vaccines for immunotherapy", J Asthma Allergy Clin Immunol, 8, pp.150~164 (1988)
- Lee KY, "Diagnosis and management of allergic disease" (2001), Hangukeuihaksa
- Calabria CW, "Accelerated immunotherapy schedules", Curr Allergy Asthma Rep, 13, pp.389~398 (2013)
- Cox L, "Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system", J Allergy Clin Immunol, 125, pp.569~574 (2010)
- Schaefer P, "Urticaria: evaluation and treatment", Am Fam Physician, 83, pp.1078~1084 (2011)
- Kemp SF, "Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization", Allergy, 63, pp.1061~1070 (2008)
- 남동호, "알레르기질환에서 면역요법의 현재와 미래", 대한의사협회지, 58(5), pp.433~440 (2015), 대한의사협회[DOI]
- Incorvaia C, "Patient's compliance with allergen immunotherapy", Patient Prefer Adherence, 2, pp.247~251 (2008)
- Nam YH, "Physician's recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy", Patient Prefer Adherence, 11, pp.381~387 (2017)
- Goldberg A, "Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy", Ann Allergy Asthma Immunol, 91, pp.405~410 (2003)
- Hejjaoui A, "Systemic reactions occurring during immunotherapy with standardized pollen extracts", J Allergy Clin Immunol, 89, pp.825~933 (1992)
- Cox L, "Allergen immunotherapy: a practice parameter third update", J Allergy Clin Immunol, 127(1 Suppl), pp.S1~S55 (2011)
- Brehler R, "Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts", Allergy Asthma Proc, 31, pp.e31~e38 (2010)
- Morais-Almeida M, "Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in paediatric age", Asia Pac Allergy, 6, pp.35~42 (2016)
- Cardona R, "Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study", Allergol Immunopathol (Madr), 42, pp.90~95 (2014)
- Portnoy J, "Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts", Ann Allergy, 73, pp.409~418 (1994)
- Akmanlar N, "Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy", Allergol Immunopathol (Madr), 28, pp.213~218 (2000)
- Kartal O, "Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey", Immunopharmacol Immunotoxicol, 37, pp.280~286 (2015)
- Gastaminza G, "Systemic reactions to immunotherapy: influence of composition and manufacturer", Clin Exp Allergy, 33, pp.470~474 (2003)
- Winther L, "Side-effects of allergen-specific immunotherapy: a prospective multi-centre study", Clin Exp Allergy, 36, pp.254~260 (2006)
- Borchers AT, "Fatalities following allergen immunotherapy", Clin Rev Allergy Immunol, 27, pp.147~158 (2004)
- Pfaar O, "Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD)", Allergo J Int, 23, pp.282~319 (2014)
